Citalopram and sertraline exposure compromises embryonic bone development.

Area of Science:

• Pharmacology
• Developmental Biology
• Orthopedics

Background:

• Selective serotonin reuptake inhibitors (SSRIs) are widely used for depression.
• Emerging evidence suggests potential risks of SSRI use during pregnancy, including birth defects.
• Serotonin receptors are present in bone cells, indicating a possible role in skeletal development.

Purpose of the Study:

• To investigate the effects of SSRI exposure on embryonic bone development.
• To determine if SSRIs impact osteoblast differentiation and activity.

Main Methods:

• Zebrafish embryos and human mesenchymal stem cells (MSCs) were treated with citalopram and sertraline.
• Bone mineralization was assessed using alizarin red staining.
• Osteoblast gene expression and apoptosis markers were analyzed via qRT-PCR.

Main Results:

• SSRI treatment in zebrafish led to decreased bone mineralization and reduced expression of mature osteoblast markers.
• In human MSCs, SSRIs decreased osteoblast activity and downregulated key osteoblast-specific genes (Runx2, Sparc, Spp1).
• No significant increase in apoptosis was observed in either model.

Conclusions:

• SSRIs appear to inhibit bone development by impairing osteoblast maturation during embryonic stages and MSC differentiation.
• These findings suggest potential risks of skeletal abnormalities in infants exposed to SSRIs in utero.
• Further research is warranted to fully understand SSRI risks during pregnancy.